ArticleJournal of neural transmission (Vienna, Austria : 1996)2015
High doses of onabotulinumtoxinA in post-stroke spasticity: a retrospective analysis.
Article in Journal of neural transmission (Vienna, Austria : 1996), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Article
- Article
- Multiple sclerosis and spasticity: the role of anaesthetic nerve blocks on rectus femoris muscle. When should stiff knee be treated with botulinum toxin?Journal of rehabilitation medicine · 2024Observational
- The Role of Botulinum Toxin Type-A in Spasticity: Research Trends from a Bibliometric Analysis.Toxins · 2024Review
- Botulinum Toxin-A High-Dosage Effect on Functional Outcome and Spasticity-Related Pain in Subjects with Stroke.Toxins · 2023Review
- Clinical efficacy of botulinum toxin type A in patients with traumatic brain injury, spinal cord injury, or multiple sclerosis: An observational longitudinal study.Frontiers in neurology · 2023Article
- European expert consensus on improving patient selection for the management of disabling spasticity with intrathecal baclofen and/or botulinum toxin type A.Journal of rehabilitation medicine · 2022Article
- Review
- High-dose Botulinum Toxin Therapy: Safety, Benefit, and Endurance of Efficacy.Tremor and other hyperkinetic movements (New York, N.Y.) · 2020Article
- Review
- Safety Profile of High-Dose Botulinum Toxin Type A in Post-Stroke Spasticity Treatment.Clinical drug investigation · 2018Review
- Benefits and Risks of Non-Approved Injection Regimens for Botulinum Toxins in Spasticity.Drugs · 2017Review
- Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study.Neurology · 2017Article
- Botulinum Toxin: Pharmacology and Therapeutic Roles in Pain States.Current pain and headache reports · 2016Review
- Spotlight on botulinum toxin and its potential in the treatment of stroke-related spasticity.Drug design, development and therapy · 2016Review
- Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity.Neuropsychiatric disease and treatment · 2016Review
- The Italian real-life post-stroke spasticity survey: unmet needs in the management of spasticity with botulinum toxin type A.Functional neurologyArticle
- Management of spasticity with onabotulinumtoxinA: practical guidance based on the italian real-life post-stroke spasticity survey.Functional neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We retrospectively evaluated the efficacy and safety of high doses of onabotulinumtoxinA (from 600 to 800 units) in 26 patients affected by upper and/or lower limb post-stroke spasticity. They were assessed before, 30 and 90 days after treatment. We observed a significant muscle tone reduction and a significant functional improvement (assessed with the Disability Assessment Scale). No adverse events were reported. In our retrospective analysis the treatment with high doses of onabotulinumtoxinA showed to be effective and safe.
Indexed as
Identifiers
25724294What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.